Personne
Yuqing Xie
Cette personne n’est plus à l’EPFL
Publications associées (6)
Engineering T Cell Trafficking and Function for Enhanced Cancer Immunotherapy
In the past decades, breakthroughs in cancer immunotherapy have led to unprecedented clinical responses in patients with advanced-stage cancers that would otherwise be fatal. However, treatment of many solid organ malignancies with highly immunosuppressive ...
EPFL2022Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion
Douglas Hanahan, Nadine Fournier, Krisztian Homicsko, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz, Jeremy Gilles Louis Guillot, Simge Yücel, Mohammad Sadegh Saghafinia, Inti Zlobec, Yuqing Xie, Dalya Ataca, Qiqun Zeng, Fleuriane Marie Tryskele Laurene Gallean, Peng Zhang, Lucine Christe
Many human cancers manifest the capability to circumvent attack by the adaptive immune system. In this work, we identified a component of immune evasion that involves frequent up-regulation of fragile X mental retardation protein (FMRP) in solid tumors. FM ...
Washington2022A Manganese Phosphate Nanocluster Activates the cGAS‐STING Pathway for Enhanced Cancer Immunotherapy
Li Tang, Yugang Guo, Yuqing Xie, Min Gao, Armand Kurum, Kewen Lei, Yu Zhao, Xiaomeng Hu, Simon Bart M. Van Herck
Targeting the stimulator of interferon genes (STING) pathway with cyclic dinucleotides (CDNs), the natural STING agonists, is a promising immunotherapeutic strategy for cancer. However, the clinical application of natural CDNs as therapeutics is greatly hi ...
2021Il10/fc fusion proteins useful as enhancers of immunotherapies
Li Tang, Yugang Guo, Yuqing Xie
The present disclosure relates to new agents useful for anti-cancer therapy such as anti-cancer adoptive T-cell transfer (ACT) immunotherapy or immune check-point blockade therapy and related compositions, uses and methods thereof. ...
2021Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells
Li Tang, Lixia Wei, Yuqing Xie, Hacer Arik
Interleukin-2 (IL-2) is a potent T-cell mitogen that can adjuvant anti-cancer adoptive T-cell transfer (ACT) immunotherapy by promoting T-cell engraftment. However, the clinical applications of IL-2 in combination with ACT are greatly hindered by the sever ...
2019Immunoengineering with biomaterials for enhanced cancer immunotherapy
Li Tang, Lixia Wei, Yuqing Xie
Cancer immunotherapy has recently shown dramatic clinical success inducing durable response in patients of a wide variety of malignancies. Further improvement of the clinical outcome with immune related cancer treatment requests more exquisite manipulation ...
2018